A Cost-Effectiveness Analysis of an Adjuvanted Subunit Vaccine for the Prevention of Herpes Zoster and Post-Herpetic Neuralgia

Mostrar otras versiones (1)

BACKGROUND: Herpes zoster (HZ) develops in up to 50% of unvaccinated individuals who live to 85 years of age, accounting for more than 1 million cases of HZ annually in the United States. A live attenuated vaccine (LAV) for HZ is U.S. FDA approved for persons 50 years or older, though CDC Advisory C...

Descripción completa

Detalles Bibliográficos
Autores principales: Carpenter, Christopher, Aljassem, Annas, Stassinopoulos, Jerry, Pisacreta, Giovanni, Hutton, David
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2017
Materias:
Abstracts
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5631538/
http://dx.doi.org/10.1093/ofid/ofx163.1043
Mostrar todas las versiones(2)

Ejemplares similares